
Dr. Ranit Kedmi, our newly-recruited PI, welcome to our Department!
The KedmiLab will explore new innovative innate immunology impacts on human disease.
The KedmiLab will explore new innovative innate immunology impacts on human disease.
CD74 as a regulator of transcription in normal B cells
Anti CTLA-4 impacts on the myeloid compartment in cancer immunotherapy.
Post translational modifications of MHCI immunopeptidome in cancer.
Personalized microbiome-driven effects of non-nutritive sweeteners on human glucose tolerance
Targeted suppression of human IBD-associated gut microbiota commensals by phage consortia for treatment of intestinal inflammation
Tumor-reactive antibodies evolve from non-binding and autoreactive precursors
Lineage Recording Reveals the Phylodynamics, Plasticity and Paths of Tumor Evolution
Tingible body macrophages arise from lymph node–resident precursors and uptake B cells by dendrites
The Dahan group and the Yosef group both awarded prestigious ERC consolidator grants to continue leading immunology research.
Fc glycoengineering of a PD-L1 antibody harnesses Fcγ receptors for increased antitumor efficacy.
A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy.
B cell class switch recombination is regulated by DYRK1A through MSH6 phosphorylation
Epithelial Nlrp10 inflammasome mediates protection against intestinal autoinflammation
The transcriptional and regulatory identity of erythropoietin producing cells.
The proteasome regulator PSME4 modulates proteasome activity and antigen diversity to abrogate antitumor immunity in NSCLC.
On receiving the Morris L. Levinson Prize in Biology.
on receiving the Scientific Council Prize for Outstanding Staff Scientists.
On receiving the Osmar Boas Medal of the German Association DGVS.
The Wein lab will explore the bacterial immune system toward new discovery in human immunology.